Private Access to Both Weight Management Options
Wegovy vs Mounjaro: Private Prescription Advantages in the UK
The NHS route for accessing Wegovy vs Mounjaro involves GP referrals, specialist weight management services, and waiting lists often exceeding 6 months. Private prescription eliminates these barriers entirely. Both medications are prescription-only medicines requiring clinical assessment, but EverydayMeds' private service provides direct access within days rather than months. Your prescriber evaluates your individual circumstances to determine which treatment—Wegovy's GLP-1 mechanism or Mounjaro's dual receptor approach—aligns with your weight management goals.
Private prescription also offers flexibility in dosing schedules and ongoing support that NHS services may struggle to provide due to capacity constraints. Both Wegovy and Mounjaro are available from EverydayMeds—your prescriber can help determine which is right for you based on your medical history, current medications, and treatment preferences. The same clinical standards apply whether accessing these treatments privately or through NHS, ensuring identical safety protocols and monitoring requirements.
Wegovy vs Mounjaro Pricing: Transparent Private Costs
Understanding the financial commitment helps inform your Wegovy vs Mounjaro decision. Wegovy pricing starts at £79.99 for the 0.25mg starter dose, progressing through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), to £209.99 for the 2.4mg maintenance dose. Bundle options provide convenience, such as the Intro Trio (0.25mg, 0.5mg, 1mg) for £299.99, covering your first 12 weeks. New customers apply discount code FIRST40 at checkout, while returning customers use DOSE25.
Mounjaro pricing follows a different structure due to its dual-agonist formulation, with costs varying by strength and supply duration. Both treatments require dose escalation over 16-20 weeks to reach maintenance levels, so budget planning should account for the full titration schedule. Private prescription eliminates hidden NHS prescription charges while providing transparent, upfront pricing that lets you plan your weight management investment accurately.
Clinical Evidence: Wegovy vs Mounjaro Trial Data
In clinical trials, patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks in the STEP 1 trial (Wilding et al., NEJM, 2021), compared to 2.4% with placebo. The STEP programme demonstrated consistent results across different populations, including those with type 2 diabetes and intensive behavioural support. Wegovy's GLP-1 mechanism showed sustained benefits over 2 years in STEP 5 studies.
Mounjaro's clinical programme utilised different trial designs and populations, making direct percentage comparisons inappropriate. Both medications demonstrated significant efficacy in their respective studies when combined with lifestyle interventions. Your prescriber considers these evidence bases alongside your individual circumstances when discussing Wegovy vs Mounjaro options during consultation.
How Wegovy Works: GLP-1 Receptor Mechanism
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural incretin hormone responsible for blood sugar regulation and appetite control. This mechanism reduces appetite by acting on brain centres that control hunger and satiety, helping you feel fuller after smaller meals. The medication may also reduce food cravings and slow gastric emptying, extending the feeling of fullness between meals. Unlike some weight management approaches, Wegovy works through established hormonal pathways your body already uses for appetite regulation. This targeted approach explains why the medication must be combined with reduced-calorie diet and increased physical activity for optimal results. The once-weekly injection schedule using Novo Nordisk's FlexTouch pen device provides consistent medication levels throughout each week.
Ordering Process: 3-Minute Assessment to Delivery
EverydayMeds streamlines the Wegovy vs Mounjaro decision process through our efficient private prescription pathway. The online clinical assessment takes approximately 3 minutes, covering medical history, current medications, and weight management goals relevant to both treatment options. Standard prescriber review occurs within 3 working days, or select express review for approval within 24 hours. Once approved, both Wegovy and Mounjaro ship via temperature-controlled, next-day delivery to preserve medication integrity. Our GPhC-registered pharmacy (#9012878) ensures all prescriptions meet identical safety standards as NHS services. No GP referral or specialist appointment is required, eliminating the traditional barriers that delay access to these prescription-only medicines.
Storage and Practical Considerations: Wegovy vs Mounjaro
Storage requirements differ between Wegovy vs Mounjaro, influencing treatment practicality for many patients. Wegovy maintains stability for up to 6 weeks at room temperature below 30°C once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. This storage advantage makes Wegovy more suitable for frequent travel or situations where refrigeration access is inconsistent. Both medications require refrigeration at 2-8°C before first use and utilise pre-filled injection pens designed for weekly administration. The mandatory dose escalation schedule applies to both treatments, starting with lower doses to minimise side effects before reaching therapeutic maintenance levels. Proper storage ensures medication potency throughout your treatment journey, regardless of which option your prescriber recommends.
Private Access Benefits: Why Choose Wegovy vs Mounjaro Privately
Private prescription for Wegovy vs Mounjaro eliminates the postcode lottery affecting NHS access across different regions. Some NHS areas provide limited access to either medication due to local commissioning decisions or capacity constraints. Private access ensures consistent availability regardless of your location or local NHS policies.
The flexibility extends to ongoing support and dose adjustments that NHS services may struggle to provide promptly. Private prescribers can respond more quickly to side effects, dosing concerns, or treatment modifications that optimise your Wegovy vs Mounjaro experience. This personalised approach often results in better treatment adherence and outcomes compared to overwhelmed NHS services managing large patient volumes with limited appointment availability.
Making Your Decision: Wegovy vs Mounjaro Consultation
Your prescriber evaluation considers multiple factors when discussing Wegovy vs Mounjaro suitability, including your medical history, current medications, lifestyle factors, and treatment goals. Some patients may be better candidates for Wegovy's established GLP-1 mechanism, while others might benefit from Mounjaro's dual receptor approach. The decision isn't simply about choosing the "better" medication—both are effective prescription-only medicines with distinct characteristics. Your consultation explores side effect profiles, injection schedules, storage requirements, and long-term treatment plans specific to your circumstances. Both Wegovy and Mounjaro are available from EverydayMeds, allowing your prescriber to recommend the most appropriate option without external constraints. Start your assessment today using discount code FIRST40 for new customers, and discover which treatment aligns with your weight management journey: https://everydaymeds.co.uk/collections/wegovy
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
